Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab Plus Radiotherapy and Chemotherapy for Locally Advanced HNSCC
NCT07447570Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: 1-year progression-free survival rate. Started Oct 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07447570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07447570.